What happens to your weight when you stop tirzepatide?
The short answer: most people regain a significant amount of the weight they lost. In the SURMOUNT-4 trial, participants who had lost an average of 20.9% of their body weight over 36 weeks on tirzepatide were then randomly assigned to either continue the drug or switch to a placebo for another 52 weeks. Those who stopped regained an average of 14.0% of their body weight during that year, while those who stayed on tirzepatide lost an additional 5.5% [4]. This means that over the full 88 weeks, the continued-treatment group lost 25.3% of their starting weight, while the withdrawal group ended up with only a 9.9% loss [4]. The pattern is clear: stopping the drug reverses most of the benefit.
A real-world study of 68 patients who had used tirzepatide for at least 12 months found similar results. After stopping, only 28% of patients maintained at least 90% of their weight loss, while 72% regained more than 10% of the weight they had lost [3]. By 9 months off the drug, patients had regained a median of 45% of their lost weight [3]. The more weight a person had lost initially, the more they tended to regain—a finding that underscores how the drug's effects are tied to continued use [3].
Do the health benefits (like blood pressure and blood sugar) last after stopping?
No—the improvements in cardiometabolic health also reverse when you stop tirzepatide, and the degree of reversal is directly linked to how much weight you regain. A detailed analysis from the SURMOUNT-4 trial tracked participants who had lost at least 10% of their weight on tirzepatide and then were switched to placebo. It found that those who regained the most weight also saw the biggest backsliding in key health measures [2]. For example, people who regained 75% or more of their lost weight saw their waist circumference increase by an average of 14.7 cm, their systolic blood pressure rise by 10.4 mm Hg, and their hemoglobin A1c (a marker of blood sugar control) increase by 0.35% [2]. In contrast, those who managed to keep their weight regain below 25% had no significant worsening in waist circumference, cholesterol, or fasting insulin levels [2]. This shows that the health benefits are not permanent—they depend on keeping the weight off.
The SURMOUNT-1 trial, which followed people with obesity and prediabetes for 3 years, provides another angle. After 176 weeks on tirzepatide, only 1.3% of treated participants had developed type 2 diabetes, compared to 13.3% on placebo—a 93% risk reduction [1]. However, after a 17-week off-treatment period, the diabetes rate in the tirzepatide group rose to 2.4%, while the placebo group stayed at 13.7% [1]. While some protective effect against diabetes persisted in the short term, the weight and metabolic improvements clearly faded once the drug was stopped.
Is there any lasting benefit at all after stopping?
The evidence for lasting benefits is very limited and mostly applies to specific situations. The SURMOUNT-1 trial hints that after 3 years of treatment, some protection against developing type 2 diabetes may persist for at least a few months after stopping—the diabetes rate in the tirzepatide group was still much lower than placebo 17 weeks off the drug (2.4% vs. 13.7%) [1]. However, this was a short follow-up, and weight regain had already begun. There is no evidence from these studies that weight loss or other cardiometabolic improvements (like lower blood pressure or cholesterol) last beyond a few months without continued treatment.
One paper discusses the potential for GLP-1 receptor agonists (a class that includes tirzepatide) to reduce cravings for addictive substances like alcohol and tobacco, based on preliminary studies [5]. If confirmed, this could represent a lasting behavioral change even after the drug is stopped, but the evidence is still too weak to draw conclusions—the only randomized trial on alcohol use showed no benefit overall, and results for smoking cessation were mixed [5]. For now, the main message from the strongest studies is that tirzepatide's benefits are tied to ongoing use.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2023 to 2025, 4 from 2024 or later, 5 in Q1 journals, collectively cited 856 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 66 papers retrieved from a database of over 500 million.
Sources used in this answer
Tirzepatide for Obesity Treatment and Diabetes Prevention
In a 3-year randomized controlled trial (SURMOUNT-1), tirzepatide led to substantial weight loss (up to 19.7%) and a 93% reduction in progression to type 2 diabetes in people with obesity and prediabetes; after a 17-week off-treatment period, the diabetes rate in the tirzepatide group rose from 1.3% to 2.4%, indicating some short-term persistence of diabetes protection but reversal of weight loss.
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity
A post-hoc analysis of the SURMOUNT-4 trial found that after tirzepatide withdrawal, the degree of weight regain directly predicted the reversal of cardiometabolic improvements; those who regained less than 25% of lost weight maintained benefits in waist circumference, cholesterol, and insulin, while those who regained more saw significant worsening.
1757-P: The Rebound Effect—Weight Regain after Tirzepatide Discontinuation
A real-world retrospective study of 68 patients found that 72% regained more than 10% of their lost weight within months of stopping tirzepatide, and greater initial weight loss was the only predictor of greater regain.
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
In the SURMOUNT-4 randomized withdrawal trial, participants who stopped tirzepatide after 36 weeks regained an average of 14.0% of their body weight over the next 52 weeks, while those who continued lost an additional 5.5%; only 16.6% of the placebo group maintained at least 80% of their initial weight loss, versus 89.5% on tirzepatide.
GLP‐1R agonist medications for addiction treatment
A review article discusses preliminary evidence that GLP-1 receptor agonists (including tirzepatide) may reduce cravings for alcohol, nicotine, and other drugs, but the only randomized trial on alcohol showed no overall benefit, and results for smoking cessation were mixed; the evidence is too preliminary to claim lasting effects after drug discontinuation.